Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPST-1495 alone or with pembrolizumab in advanced solid tumors
NCT04344795Phase 1Completed
- Sponsor
- Tempest Therapeutics
- Start
- May 2020
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tpst-1495 in solid tumor, colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and 6 more (5 arms), sponsored by Tempest Therapeutics. Primary endpoint: Maximum Tolerated Dose and/or Recommended Phase 2 Dose up to 24 months. Started May 2020; status: completed.
02
Drugs
tpst-1495
03
Conditions
solid tumorcolorectal cancer (CRC)non-small cell lung cancer (NSCLC)squamous cell carcinoma of the head and neck (HNSCC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04344795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04344795.